Enrique Soler, director of the Pharmacy Service of the Arnau de Villanova Hospital in Valencia, stated at the School of Pharmacy of the University of Navarra that"the new hepatitis C treatment would be justified for the most severe patients". According to the expert, scientific publications such as the British Medical Journal or Prescrire indicate that the benefits of the drug sofosbuvir "have not yet been shown to cause long-term clinical improvement". He explained this at the lecture "Drug financing from an ethical perspective. The treatment of hepatitis C", organized by the seminar of Humanities Pharmaceuticals of the academic center.

About thirty people attended the meeting focused on the ethical analysis of the distribution of healthcare resources. issue In this regard, Dr. Soler pointed out that "we cannot finance everything, limits must be placed on what does not serve the fundamental good of the patient, always trying to benefit as many people as possible, that is to say, maximize the benefit". 

The overpricing of sofosbuvir (trade name Sovaldi) raises an ethical controversy, as well as a social one: "the treatment offers a significant improvement but there is still a lack of data to confirm its effectiveness and long-term safety deadline to offer access to all those affected," says the expert.

Chronic infection by the hepatitis C virus has a prevalence of around 2.2% of the population and affects 85 million people in the world, and can progress to cirrhosis and liver cancer. In Spain there are between 700,000 and 800,000 people affected and the approximate cost per patient ranges between 40,000 and 150,000 euros, with 90% elimination of the virus.